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Abstract
Background: This study aimed to estimate the cost-effectiveness of extracorporeal cardiopulmonary resuscitation (ECPR) for in-hospital cardiac arrest
treatment.
Methods: A decision tree and Markov model were constructed based on current literature. The model was conditional on age, Charlson Comorbidity
Index (CCI) and sex. Three treatment strategies were considered: ECPR for patients with an Age-Combined Charlson Comorbidity Index (ACCI) below
different thresholds (2–4), ECPR for everyone (EALL), and ECPR for no one (NE). Cost-effectiveness was assessed with costs per quality-of-life
adjusted life years (QALY).
Measurements and main results: Treating eligible patients with an ACCI below 2 points costs 8394 (95% CI: 4922–14,911) euro per extra QALY per
IHCA patient; treating eligible patients with an ACCI below 3 costs 8825 (95% CI: 5192–15,777) euro per extra QALY per IHCA patient; treating eligible
patients with an ACCI below 4 costs 9311 (95% CI: 5478–16,690) euro per extra QALY per IHCA patient; treating every eligible patient with ECPR costs
10,818 (95% CI: 6357–19,400) euro per extra QALY per IHCA patient. For WTP thresholds of 0–9500 euro, NE has the highest probability of being the
most cost-effective strategy. For WTP thresholds between 9500 and 12,500, treating eligible patients with an ACCI below 4 has the highest probability of
being the most cost-effective strategy. For WTP thresholds of 12,500 or higher, EALL was found to have the highest probability of being the most cost-
effective strategy.
Conclusions: Given that conventional WTP thresholds in Europe and North-America lie between 50,000–100,000 euro or U.S. dollars, ECPR can be
considered a cost-effective treatment after in-hospital cardiac arrest from a healthcare perspective. More research is necessary to validate the
effectiveness of ECPR, with a focus on the long-term effects of complications of ECPR.
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Cardiac arrest, cardiopulmonary arrest, or circulatory arrest is the loss
of effective blood circulation, which inevitably leads to death if
cardiopulmonary resuscitation (CPR) is not started. Cardiac arrest is
usually divided based on location into out-of-hospital cardiac arrest
(OHCA) and in-hospital cardiac arrest (IHCA). OHCA is described to
occur around 19–104 times per 100,000 population per year and
results in 10% survival at hospital discharge.1 The incidence of IHCA is
1–6 events per 1000 hospital admissions2–4 and recent meta-analyses
showed a pooled survival to discharge of 15% (ranging from 3% to
40%) and a one-year survival of 13% (ranging from 4% to 69%).5,6
Patient-specific factors associated with survival are age,7,8 comor-
bidities9–12 and presence of shockable rhythm.13
A possible advantage for patients suffering IHCA versus OHCA is
that hospitals are equipped with advanced life support teams, who
could employ extracorporeal cardiopulmonary resuscitation (ECPR)
using veno-arterial extracorporeal membrane oxygenation (VA-
ECMO). This technique has seen an increase in use over the last
decades.14,15 By taking over cardiac and respiratory function, VA-
ECMO ensures oxygenation and circulation.16 Although evidence
from randomized controlled trials is lacking,17 observational studies
have repeatedly shown an increase in survival after ECPR compared
to conventional CPR.18–20 Furthermore, the American Heart associa-
tion recommends the in-hospital use of ECPR in patients with a
reversible cause of CA (e.g.: acute coronary syndrome).
When assessing whether or not to implement ECPR, cost-
effectiveness should be taken into account. Ethical and economic
considerations are of increasing importance in decision making
pertaining to intensive care allocation.21 Financial resources are
limited and health care should be focused more on therapies that do
not only extend life, but rather offer a reasonable health-related quality
of life (HRQoL). This study was designed to provide cost-effectiveness
evidence for international comparison and to provide an overview of
current knowledge of the economic aspects of ECPR.
Two small observational studies (US and Australia) have shown
indications of cost-effectiveness of ECPR for both OHCA and IHCA.22,23
There are however several caveats. Because of low sample size and
estimates pertaining to local situations these studies are not likely to be
generalizable to all settings. Furthermore, for the in-hospital and out-of-
hospital setting, effectiveness should be assessed separately.
The primary aim of this study was therefore to assess the cost-
effectiveness of ECPR treatment after IHCA based on current
literature. By using all available evidence, this modelling approach
would ensure a high generalizability of our results. For this purpose, a
decision tree and Markov model were developed. Both models are
frequently used in health-economic evaluations, because they are
able to calculate quality of life adjusted life years (QALY).24,25 The
secondary aim was to assess in which patient group ECPR is most
likely to be cost-effective.
Methods
This cost-effectiveness evaluation is reported according to the
CHEERS reporting guidelines.26 We searched PubMed for relevant
studies to inform on all parameters used for the models. We used the
search terms “in-hospital cardiac arrest” and “extracorporeal cardio-
pulmonary resuscitation” in combination with the specific parameter of
interest. Furthermore, we found literature using the reference list of
already found studies.
Decision tree
A three-strategy decision tree was created, which encompasses the
in-hospital phase. This type of model uses known absolute and
relative risks to calculate the probability of an outcome. The decision
tree calculates the probability of dying before discharge. The
strategies considered were ECPR for no one (NE), ECPR for every
eligible patient (EALL) and ECPR for eligible patients with an Age-
Combined Charlson Comorbidity Index (ACCI) score below a certain
threshold (EACCI_lo). The thresholds for the ACCI analysed ranged
from two to four: patients with an ACCI above the threshold did not
receive ECPR. The ACCI thresholds have been based on best
available ECPR guidelines to exclude patients with a terminal illness,
comorbidities that form a contraindication for ICU admission or for
intravascular cannulation.27 Furthermore patients >75 years of age
are generally not considered eligible. The ACCI score is described in
Table 1, Supplement 1.
The ACCI threshold can be illustrated by the following example: a
patient of 50 years old with moderate renal disease (GFR<40 mL/min/
1.73 m2) will have an ACCI of 3. If the patient would suffer a myocardial
infarction the score will rise to 4.
The decision tree consists of multiple nodes with probability
estimates found in literature (Fig. 1 and Table 1). The first node
represents patients with a Do-Not-Resuscitate (DNR) status. This is
Fig. 1 – Decision tree of the in-hospital phase of the model. For the assumed probabilities (P), odds ratio’s (OR), relative
risks (RR), and betas, see Table 1. DNR = do-not-resuscitate; CPR = cardiopulmonary resuscitation; ROSC = return of
spontaneous circulation.
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an agreement between a patient and a health care professional not to
attempt cardiopulmonary resuscitation in case of cardiac arrest. Since
a DNR status is more often agreed upon by patients with higher age,28
we assumed higher probabilities for higher aged patients. We
assumed that for patients who suffered cardiac arrest with a DNR
status, no CPR would be attempted and death is certain. When
patients did not have a DNR status, CPR would be attempted. The
next node represents the probability of having a contra-indication for
ECPR. Having a contra-indication, e.g. refractory cardiac disease or
metastatic cancer, was assumed to increase the risk of dying after
CPR. If CPR was started and no contra-indication was present, the
next node represents the probability of having return of spontaneous
circulation (ROSC) within 20 min after cardiac arrest.29 If ROSC would
not be achieved within 20 min, ECPR could be started and could
increase the remaining survival probability.18 The probability of having
a complication of ECPR and the probability of subsequent death are
also taken into account.30–32 These probabilities were calculated from
the ELSO database.33 The extra probability of mortality, given that the
patient had a complication was: the mortality rate of patients with a
complication minus the overall mortality rate. Finally, the mortality rate
after CPR increases with increasing Age-Combined Charlson
Comorbidity Index (ACCI).9,10
The prevalence of DNR status below 75 years was assumed to
be around 5% (range 2–10%), based on experience in our
hospital: the Erasmus Medical Center, Rotterdam. The
probability of having a contra-indication for ECPR was also based
on experience in our hospital, where we implemented ECPR in
2016. We assumed that 20% (range 10–30%) of the patients have
the contra-indications described by Makdisi et al. Since the
described contra-indications (e.g. refractory cardiac disease or
metastatic cancer) are severe conditions, the risk of dying was
assumed to double (OR: 2.0, with a minimum of 1.4, and a
maximum 2.9).
Markov model
For the calculation of long-term outcomes, a Markov model was used.
A Markov model uses states and transition probabilities to calculate
long-term outcomes.24 We propose a model consisting of two states:
an alive state (with decreased HRQoL) and a dead state (the
absorbing state). Markov models can be used to calculate the time
spent in each state. Therefore, QALYs can be calculated, making this
type of model useful for cost-effectiveness analysis.25 Each individual
probability of dying at the end of the decision tree described above is
used as input in the subsequent Markov model. The model simulated
20 years of follow-up and the model cycles were one year long. The
data on age and sex specific mortality rates were provided by Statistics
Netherlands (CBS).34 We did not assume a lasting effect of IHCA on
long-term survival.35 The amount of life-years were then multiplied by
the sex-specific utility score after IHCA to obtain QALYs for men and
women36 (Table 1).
As an example, consider a patient with a 100% chance of surviving
the in-hospital phase: the Markov model will calculate the amount of
life years this patient will spend after discharge. For a patient with 0%
Table 1 – Assumed estimates and their distributions for the decision tree in the probabilistic sensitivity analysis.
Abbr. Parameter Median (IQR) Distribution Source
Decision tree
P1 Probability of having DNR status if <75
years
0.05 (0.02–0.10) Beta(5,95) Clinical insight
P2 Probability of ECPR contraindication 0.19 (0.11–0.32) Beta(10,40) Clinical insight
P3 The probability of dying after CPR 0.85 (0.83–0.87) Beta(850,150) Zhu and Zhang
5
P4 The probability of having ROSC within
20 min
0.38 (0.35–0.41) Beta(338,556) Khan et al.29
P5 Probability of complication 0.38 (0.29–0.47) Beta(38,62) Sheu et al., Muller et al. and
Sakamoto et al.30–32
P6 Probability of dying because of
complication
0.2 (0.1–0.32) Beta(10,40) Clinical insight
RR1 The relative risk of dying, ECPR vs non
ECPR
0.43 (0.3–0.62) Lognormal(0.85,
0.19)
Chen et al.18
OR1 OR of dying when contraindication for
ECPR
2.00 (1.40–2.93) Lognormal(0.69,
0.2)
Clinical insight
OR2 OR of having DNR status if 75 - 84
years, compared to <75 years
1.71 (1.23–2.32) Lognormal(0.53,
0.16)
Cook et al.28
OR3 OR of having DNR status if >85 years,
compared to <75 years
2.98 (2.38–3.75) Lognormal(1.09,
0.12)
Cook et al.28
Beta1 The log odds increase in dying per ACCI
increase
0.09 (0.03–0.14) Log-Lognormal
(0.09, 0.03)
Hirlekar et al.9
Costs and utilities
In-hospital incremental cost of ECPR
after cardiac arrest
51756.66
(31377.83–
73978.21)
Normal(51997,
10767)
Oude Lansink-Hartgring
et al.37
Utility score for men 0.79 (0.69–0.87) Triangle(a = 0.66,
b = 0.89, c = 0.82)
Israelsson et al.36
Utility score for women 0.74 (0.62–0.81) Triangle(a = 0.58,
b = 0.82, c = 0.81)
Israelsson et al.36
ECPR = extracorporeal cardiopulmonary resuscitation; CPR = cardiopulmonary resuscitation; ROSC = return of spontaneous circulation; ACCI = Age-Combined
Charlson Comorbidity Index; DNR = do not resuscitate.
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chance of surviving the in-hospital phase, the Markov model will
estimate 0 life years after discharge. For chances between 0% and
100%, the model calculates the average life years that patients with
the same characteristics will spend after discharge.
Cost-effectiveness analysis
The total costs of ECPR were calculated based on how many patients
received ECPR following the decision tree outcomes: a patient
received ECPR according to the treatment strategy if they did not have
a DNR status, no contra-indication, and no ROSC within 20 min (Fig. 1
and Table 1).
Only direct additional costs of ECPR treatment were taken into
account, taking a health care’s perspective. The average additional costs
of ECPR described in the literature were used in the model. A detailed
description of the items included in the total costs has been described by
Lansink-Hartgring et al.37 A discount rate of 4% was applied, the
appropriate rate for cost-effectiveness analyses in the Netherlands.38 To
assess cost-effectiveness of the strategies, incremental cost-effective-
ness ratios (ICER) were calculated, where NE serves as the reference
category. The ICER informs about how many extra euro per QALY a
strategy costs, compared to NE. The incremental costs and QALYs were
plotted and the cost-effectiveness acceptability curves were calculated
and drawn to obtain the most cost-effective strategy.
Important to take into account is that the calculated costs for ECPR
are notably lower than the costs of ECMO. This is due to the model
structure, in which costs are calculated for an average patient who
suffers IHCA, thereby including also patients who do not receive
ECPR.
Probabilistic sensitivity analysis
To take the uncertainty of our model parameters into account, a
probabilistic sensitivity analysis (PSA) was performed. A PSA repeats
the model a large number of times with different (but probable)
parameters. The type of distributions that were used were beta
distributions for probabilities, log-normal distributions for the odds ratios
and relative risks, and log–log-normal distribution for the log-odds
increase in mortality for an ACCI point increase. The characteristics of
the distributions were adjusted so that the median and interquartile
range were identical to the estimate and 95% confidence interval. The
type and characteristics of the distributions of the parameters are
described in Table 1. From these distributions, 1000 random samples
were drawn, resulting in 1000 replicates of the model. Additionally, a
representative cohort of 1000 patients was randomly sampled
(Table 2).10,39 After running the 1000 replicates of the model in this
cohort, outcomes were calculated 1000 times. We calculated the
QALYs and costs per strategy. The median was taken as the most
probable estimate of the model. The 2.5th and 97.5th percentile were
calculated, which indicated the borders of the 95% credibility interval.
To estimate whether the conclusions were affected by the
parameters that were not found in literature, linear regression was
performed. As the dependent variable, the ICER of the EALL strategy
per iteration was used. As predictors, the standardized parameter
values were used. The coefficients of the model could therefore be
interpreted as “with one standard deviation (SD) increase in the
parameter, the ICER for the EALL strategy increases with x”.
All analyses were performed using R (R Core Team (2013). R: A
language and environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria). For the Markov model, the
“dampack” package was used.40 The code of the model is online
available in Appendix 2, for transparency and reproducibility.41
Results
In the decision tree, survival rates between 9% and 13% were
observed for the NE strategy, and between 30% and 35% for the EALL
strategy (Fig. 1, Supplement 1). After applying a Markov model,
expected life years after CPR per patient for the NE strategy ranged
from 0.79 to 2.48 and for the EALL strategy from 2.57 to 6.55 years
(Fig. 2, Supplement 1).
The expected costs per ICHA patient for treating eligible patients
below an ACCI of 2 points with ECPR are 3975 (95% CI: 2418–5780)
euro, and increased to 23,272 (95% CI: 14,159–33,838) euro for
treating all eligible patients (Table 3). The associated QALYs for
treating no patients with ECPR are 1.2 (95% CI: 1.0–1.5); for treating
eligible patients below an ACCI of 2 points 1.7 (95% CI: 1.4–2.0); for
treating eligible patients below an ACCI of 3 points 2.1 (95% CI: 1.7–
2.6); for treating eligible patients below an ACCI of 4 points 2.6 (95%
CI: 2.0–3.2); and for treating all eligible patients 3.4 (95% CI: 2.4–4.2).
Table 2 – Patient characteristics of the simulated
cohort, based on literature.10,39
Characteristic N = 1000
Age (mean (sd)) 65.49 (15.71)
Male (%) 578 (57.80)
CCI (%)
0 373 (37.30)
1 230 (23.00)
2 183 (18.30)
3 107 (10.70)
4 43 (4.30)
5 40 (4.00)
6 15 (1.50)
7 4 (0.40)
8 5 (0.50)
CCI = Charlson Comorbidity Index.
Table 3 – The health economic evaluation for each
strategy.
Strategy Costsa QALY ICERb
NE – 1.2 (1.0–1.5) –
ACCI < 2 3975 (2418–5780) 1.7 (1.4–2.0) 8394 (4922–14,911)
ACCI < 3 8066 (4909–11,731) 2.1 (1.7–2.6) 8825 (5192–15,777)
ACCI < 4 12,942 (7881–18,829) 2.6 (2.0–3.2) 9311 (5478–16,690)
EALL 23,272 (14,159–33,838) 3.4 (2.4–4.2) 10,818 (6357–19,400)
The strategies are nobody ECPR (NE), treating everyone with an Age-
Combined Charlson Comorbidity Index (ACCI) of 2, 3 or 4 or less, and
treating everyone with ECPR (EALL). The ranges indicate 95% credibility
intervals (CI).
a In Euro, only direct additional ECPR costs.
b The incremental cost-effectiveness ratio (ICER) is calculated with the
most conservative method (NE: nobody ECPR) as the reference method. It
represents the costs per extra QALY.
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Compared to treating NE, the expected incremental costs per extra
QALY (ICER) for treating eligible patients with an ACCI below 2 points
is 8394 (95% CI: 4922–14,911) euro per extra QALY; for treating
eligible patients with an ACCI below 3, the ICER is 8825 (95% CI:
5192–15,777) euro per extra QALY compared to NE; for treating
eligible patients with an ACCI below 4, the ICER is 9311 (95% CI:
5478–16,690) euro per extra QALY; for treating all eligible patients, the
ICER was 10,818 (95% CI: 6357–19,400) euro per extra QALY.
Table 3 displays an overview of the economic evaluation. The
considered strategies are comparable in terms of mean ICER, but the
incremental costs and incremental QALYs vary significantly between
the considered strategies (Fig. 3, Supplement 1).
The cost-effectiveness acceptability curves depicted in Fig. 2 show
that for WTP thresholds of 0–9500 euro, NE has the highest probability
of being the most cost-effective strategy. For WTP thresholds between
9500 and 12,500, treating eligible patients with an ACCI below 4 has the
highest probability of being the most cost-effective strategy. For WTP
thresholds of 12,500 or higher, EALL was found to have the highest
probability of being the most cost-effective strategy.
The only parameter that was found to influence the cost-effectiveness
significantly was the relative risk of dying of ECPR (effect of one unit
increase of the parameter on the ICER was 255 (481 to 28) euros
per incremental QALY), see Table 2, Supplement 2.
Discussion
In this studywefoundthat theexpected costs per IHCApatientof treating
each eligible IHCA patient with ECPR are approximately 23,000 euro. A
patientwaseligiblewhennocontraindicationswas present, and in whom
ROSC cannot be achieved within 20 min after cardiac arrest. Per QALY
increase, the associated costs were around 15,000. The Willingess-To-
Pay tresholds in Europe and North-America are between 50,000–
100,000 euro per incremental QALY. Within this range, performing
ECPR in every eligible IHCA patient, is likely to be costs-effective.
The use of ECMO has steadily increased from 2007 onwards.14
Positive results from observational studies and increasing clinical
applicability led to the inclusion of ECPR in the Advanced Life Support
Guidelines by the European Resuscitation Counsil.42 However,
ECPR is costly and labour-intensive and careful economic evaluation
was still lacking.
Because ECPR was found to be cost-effective, this study
substantiates its increased implementation and inclusion as possible
treatment in the guidelines. The allocation of intensive care treatments
should be critically evaluated, especially when financial resources are
limited.21 The difference in survival probability after ECPR seems to
be sufficient to render the therapy cost-effective. Because we
performed an analysis taking all uncertainties of parameters into
account, we believe that we reliably estimated the average cost per
IHCA patient when every eligible patient is treated with ECPR: around
11,000 euro per extra QALY.
Our cost-effectivenessanalysis based on literaturesupports findings
of empirical studies. Firstly, our study confirms the results of a recent
small retrospective study in the United States that suggested that ECPR
after IHCA is cost-effective, considering only in-hospital costs.22 This
study suggested that the costs per extra QALY saved is around 56,000
U.S. dollars. This estimate is larger than our estimate of 11,000 euros,
but health care expenditures in the United States tend to be higher than
in Europe.43 Nevertheless, it is reassuring that both studies conclude
that ECPR after IHCA is cost-effective, since they both assess primarily
in-hospitalcosts.Secondly,ourstudyconfirmstheresultsofDennisetal.
Fig. 2 – Cost-effectiveness acceptability curves. For given willingness to pay (WTP) thresholds, the probability of being
the most cost-effective strategy is plotted. The strategies are nobody ECPR (NE), treating everyone with an Age-
Combined Charlson Comorbidity Index (ACCI) of 2, 3 or 4 or less (thr2, thr3, thr4 respectively), and treating everyone
with ECPR (EALL). The dotted lines indicates the WTP thresholds of 9500 and 12,500.
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This study showed that for IHCA, 15,000 euros (25,000 AUD) per extra
QALY was expected, which is similar to our estimate.23
The results of our study are also similar to results of the cost-
effectiveness of a mobile ECPR team.44 This team is able to treat
patients with ECPR in multiple centres, and its application was found
to be potentially cost-effective. The application could benefit centres
that do not have the resources for ECPR or lack experience with its
application. Centres that often use ECPR rely on perfusionists for aid
in initiation and maintenance of treatment, which enhances the costs.
Therefore, it could well be that ECPR is mostly cost-effective when
there is no need for these extra costs. This hypothesis, however,
warrants further investigation.
The range of costs of ECMO found in the literature is large.45
Mostly because studies inconsistently report their results, there are no
factors described that explain this variation. We used a structured
Dutch study as input for our cost-effectiveness analysis, since it
describes clearly the incremental costs for ECPR.37 This study found
that the majority of the costs are composed of nursing days. Being able
to shorten the length of ICU stay would therefore enhance cost-
effectiveness of ECPR after IHCA.
We did not find that treating a subgroup of IHCA patients with
ECPR based on Age-Combined Charlson Comorbidity Index affected
cost-effectiveness. Since others described that cost-effectiveness
depends on patient characteristics,44 we consider this to be attributed
to two factors. First, the effect of comorbidity on survival of CPR is
uncertain.10,46 More research into this relationship is necessary.
Second, if there is an effect of comorbidity, this effect is more likely to
be significant in a cohort with a high prevalence of comorbidities. The
prevalence in our representative cohort, however, was low.10,39
This study has several limitations. Unfortunately, not all information
needed for the model could be found in the literature. The lack of
evidence had two consequences. First, it was necessary to base some
of the parameters on clinical knowledge; e.g., for the probability of
having a contraindication for ECPR. However, a sensitivity analysis
showed that these parameters were not likely to influence the overall
cost-effectiveness of ECPR. Second, cost-effectiveness might be
somewhat overestimated. Evidence from randomized controlled trials
was unfortunately absent at this moment.17 Observational studies
could have overestimated the effect of ECPR on survival because of
confounding bias.18,19 An overestimated effect of ECPR would result in
an overestimated cost-effectiveness. Additionally, we were not able to
model long-term effects of complications of ECPR: the extra health care
costsand lower qualityof life after major complications of ECPR (stroke,
acute kidney injury) could decrease overall cost-effectiveness.
Although we did not take non-direct costs of ECPR into account,
we still believe this study provides a valid economic evaluation. Other
identifiable costs are costs of rehabilitation, future health care costs
and non-medical costs such as loss of participation in working life.
However, these costs are more interesting from a societal perspective
than a health care perspective. Other costs that are not taken into
account are the costs of implementation. These expenses are large
and could explain the stagnating increase in the use of ECPR.47,48
Therefore, we believe that our findings are most applicable to large
hospitals in western countries, which often do have access to these
resources to overcome the first barrier to an apparent cost-effective
therapy.
We believe future studies should have three goals. First, to identify
patients who could benefit most from ECPR. Second, randomized
controlled trials are necessary, as indicated in the advanced life support
guidelines.42 Fortunately, five ongoing randomized controlled trials will
hopefully fill thisknowledge gap in the upcomingyears.20 Third, the long-
term effects of complicationsof ECPRshould be investigated, sincethey
could decrease the cost-effectiveness of the intervention. The
knowledge gained from further research could improve implementation
and cost-effectiveness of this costly and labour-intensive intervention.
Conclusion
For in-hospital cardiac arrest patients, extracorporeal cardiopulmo-
nary was demonstrated to be cost-effective from a healthcare
perspective given that conventional WTP thresholds lie between
50,000–100,000 euro or U.S. dollars. More research is necessary to
validate the effectiveness of ECPR, with a focus on the long-term
effects of complications of ECPR.
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